BN Business News
Add your company to Business Communicator →

Innovation & intellectual property · 17/11/20261 min read

Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors

EDITORIAL ILLUSTRATIONI&Innovation & intellectual propertyBN
Illustration generated by Business News; it is not a source photograph.

Summary

ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 — Ichnos Glenmark Innovation, Inc. (IGI), a...

Original source language: PR Newswire UK — News ReleasesOpen original release →

Explore insights

Business insights →